Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial.
نویسندگان
چکیده
In the 2005-01 trial, we have demonstrated that bortezomib-dexamethasone as induction therapy before autologous stem cell transplantation was superior to vincristine-adriamycin-dexamethasone. We conducted a post-hoc analysis to assess the prognostic impact of initial characteristics as well as response to therapy in patients enrolled in this study. Multivariate analysis showed that ISS stages 2 and 3 and achievement of response less than very good partial response (VGPR) both after induction therapy and after autologous stem cell transplantation were adverse prognostic factors for progression-free survival, the most important one being achievement of response less than VGPR after induction. Progression-free survival was significantly improved with bortezomib-dexamethasone induction therapy in patients with poor-risk cytogenetics and ISS stages 2 and 3 compared with vincristine-adriamycin-dexamethasone. In these 2 groups of patients, achievement of at least VGPR after induction was of major importance. This study is registered with EudraCT (https://eudract.ema.europa.eu; EUDRACT 2005-000537-38) and http://clinicaltrials.gov (NCT00200681).
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Brief report Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial
Brief report Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial Philippe Moreau,1 Michel Attal,2 Brigitte Pégourié,3 Lucie Planche,1 Cyrille Hulin,4 Thierry Facon,5 Anne-Marie Stoppa,6 Jean-Gabriel Fuzibet,7 Bernard Grosbois,8 Chantal Doyen,9 Nicolas Ketterer,10 Catherine Sebban,11 Brigitte Kolb,12 Carine Chaleteix,13 Mamoun Dib,14...
متن کاملSubcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma.
High-dose therapy plus autologous stem cell transplantation (ASCT) is considered the standard of care for the front-line treatment of younger patients with multiple myeloma. Response rates to induction therapy prior to ASCT have significantly increased through the use of novel agent-based combinations. Based on response rates, depth of response, and progression-free survival as surrogate marker...
متن کاملComplete response after autologous stem cell transplant in multiple myeloma
We evaluated long-term outcome of patients achieving complete response (CR) after autologous stem cell transplantation (ASCT) for multiple myeloma. Between April 1990 and June 2012 191 patients underwent ASCT. The median age was 53 years (range, 26-68 years), 135 were men. Pretransplant, patients received induction therapy with VAD (vincristine, doxorubicin, dexamethasone; n = 77), novel agents...
متن کاملBortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
PURPOSE To compare efficacy and safety of bortezomib plus dexamethasone and vincristine plus doxorubicin plus dexamethasone (VAD) as induction before stem-cell transplantation in previously untreated myeloma. PATIENTS AND METHODS Four hundred eighty-two patients were randomly assigned to VAD (n = 121), VAD plus dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) consolidation (n ...
متن کاملLateral ventricule invasion and radiation dose to subventricular zone: Their impact to the treatment outcomes of glioblastoma
Background: This study was conducted to evaluate the recurrence patterns of GBM in regard to its contact with LVs, the relation between radiation doses to subventrivular zone (SVZ). Materials and Methods: Between 2012 and 2014, 80 adult patients with GBM were included this trial. Median follow-up period was 15 months. Median tumor size was 4.5 cm (1.3-8 cm), where 58% of the patients had a tumo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Blood
دوره 117 11 شماره
صفحات -
تاریخ انتشار 2011